Drug intelligence / Profile preview

azacitidine + idarubicin

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

A combination therapy consisting of azacitidine, a hypomethylating agent that inhibits DNA methyltransferase, and idarubicin, an anthracycline antineoplastic agent. This combination is used in the treatment of acute myeloid leukemia (AML), particularly in newly diagnosed patients. Azacitidine works by causing hypomethylation of DNA at low doses and through direct cytotoxicity at higher doses by incorporating into DNA and RNA. Idarubicin functions as an anthracycline that intercalates with DNA, inhibiting topoisomerase II and disrupting DNA replication and transcription.

Other names: azacitidine and idarubicinAZA-PLUS regimen

Targets

DNMT (DNA methyltransferase)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on azacitidine + idarubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azacitidine + idarubicin.

Explore the full profile